beroe-ai

Lab Animals
Market, Supplier, Risk and
Competitive Intelligence

Manage Lab Animals Category with Ai powered
Procurement Productivity Suite

meet-abi-1

Abi will answer all Lab Animals related
procurement queries with relevant data points

Abi - AI powered digital procurement assistant

discover-market-info

Get up-to-date market and supplier info on Lab Animals to help you build

Intelligence covers market and price outlook, SWOT analysis, demand & supply drivers, engagement models and Procurement best practices

1

Intelligence on category covers the following aspects market outlook, supply market, SWOT analysis, Cost components & Price outlook, Demand and supply drivers, Engagement Models and Procurement Best Practices

manage-risk

Assess Supplier Risk based on key risk and compliance parameters

1

Supplier assessment covers the following parameters Financial Risk, Ethical, Labor, Environmental Compliance, IT Security.

2

Supplier assessment is powered by world’s leading data partners including D&B, CreditSafe, Dow Jones, Refinitiv, Orpheus

discover-supplier

Identify right fit suppliers based on your selection criteria including revenue, capabilities, certification, geography

1

Select suppliers based on industry, country, classification from a database of 4.2 mn suppliers. Get detailed supplier profiles with supplier capabilities, revenue, certifications, risk ratings

assess-category-perforamnce

Benchmark your category performance against peers and the market

1

Measure category performance on 15 key parameters across cost, risk and strategy KPIs

source-market-indices

Get information on key factors affecting your supply

1

Source Macro Data and Market Indices information from leading data sources across these key areas - Labor Rates, Currency, Energy, Country Risk, Trade Flow/Transportation, Port Data, Tariff, Weather and Epidemics

meet-abi-1

Abi will answer all Lab Animals related
procurement queries with relevant data points

Abi - AI powered digital procurement assistant

discover-market-info

Get up-to-date market and supplier info on Lab Animals to help you build

Intelligence covers market and price outlook, SWOT analysis, demand & supply drivers, engagement models and Procurement best practices

1

Intelligence on category covers the following aspects market outlook, supply market, SWOT analysis, Cost components & Price outlook, Demand and supply drivers, Engagement Models and Procurement Best Practices

manage-risk

Assess Supplier Risk based on key risk and compliance parameters

1

Supplier assessment covers the following parameters Financial Risk, Ethical, Labor, Environmental Compliance, IT Security.

2

Supplier assessment is powered by world’s leading data partners including D&B, CreditSafe, Dow Jones, Refinitiv, Orpheus

discover-supplier

Identify right fit suppliers based on your selection criteria including revenue, capabilities, certification, geography

1

Select suppliers based on industry, country, classification from a database of 4.2 mn suppliers. Get detailed supplier profiles with supplier capabilities, revenue, certifications, risk ratings

assess-category-perforamnce

Benchmark your category performance against peers and the market

1

Measure category performance on 15 key parameters across cost, risk and strategy KPIs

source-market-indices

Get information on key factors affecting your supply

1

Source Macro Data and Market Indices information from leading data sources across these key areas - Labor Rates, Currency, Energy, Country Risk, Trade Flow/Transportation, Port Data, Tariff, Weather and Epidemics

Get Beroe LiVE.Ai™ subscription for your team

17k + companies trust Beroe for their supply market intelligence needs

Check out what’s included in market information for Lab Animals on Beroe LiVE.Ai™

Learn More about Beroe LiVE.Ai™

Table of Contents

  1. Lab Animals Global Market Summary
  2. Lab Animals Executive Summary​
  3. Lab Animals - COVID Impact Update​
  4. Lab Animals Negotiations Leverage​
  5. Talking Points to Business: Lab Animals

 

  1. Lab Animals Market Analysis
  2. Market Snapshot: Lab Animals​
  3. Lab Animals Industry Trends​
  4. Lab Animals Regional Analysis
  5. Procurement-Centric Five Forces Analysis on Lab Animals

 

  1. Lab Animals - Cost Drivers and Cost Structures 
  2. Lab Animals - Cost and Pricing Model ​
  3. Lab Animals - Cost Drivers and Cost Structure

 

  1. Lab Animals Market Monitoring Insights 
  2. Lab Animals Billing Rates Overview​
  3. Lab Animals: Billing Rates​
  4. Lab Animals: Billing Rates: Methodology

 

  1. Lab Animals Sourcing Practices 
  2. Lab Animals Sourcing Overview

 

  1. Lab Animals Purchasing Process
  2. Lab Animals - RFI Builder

 

  1. Lab Animals Supplier Section
  2. Lab Animals - Key Global Suppliers: Global Supplier List and Capabilities​
  3. Lab Animals - Key Global Supplier Profile​
  4. Lab Animals - Key Global Supplier: SWOT

 

  1. Lab Animals Innovation Framework 
  2. Lab Animals Innovation

 

  1. Lab Animals Sustainability
  2. Lab Animals Sustainable Initiatives

Want a more detailed personalised report?

Lab Animals Global Market Outlook

  • There is an Increase in demand for effective animal model to validate efficacy and non toxicity of drugs and vaccines in the pipeline

  • Large pharmaceuticals are outsourcing the service to two or three suppliers and using niche players wherever necessary based on their study requirements

  • The focus is on 3R (Replace, Reduce, Refine) principle and pushing towards novel technology therapeutic models, and alternatives to non-animal models

Impact of COVID-19 on Lab Animals Industry

  • The COVID-19 pandemic has created an unprecedented global public health challenge. It has also expressed a favorable influence on the animal model market for vaccine and antiviral medication research and development. Since early 2021, post pandemic recovery is highly prevalent in the animal market and is likely to provide CROs with additional prospects.

  • Modified Mouse Models: COVID-19 rodent models, particularly humanised ACE2 (hACE2) mice, which express humanised ACE2 in the airway and other epithelia and develop a deadly SARS-CoV infection, are in high demand. This model is currently used for vaccine toxicity and efficacy evaluation and also to tests drugs to combat the pandemic

  • Increased Funding and Investment: Many governments and scientific research institutions are likely to expand research funding for vaccines and therapies for contagious diseases, like COVID-19

  • Demand of Suppliers: Demand of cell therapy and immuno-oncology screening Models have increased in the APAC region, due to expanding R&D facilities in the low cost regions

Procurement-Centric Five Forces Analysis on Lab Animals Industry

The lab animals market is a highly fragmented supply chain, giving sponsors high bargaining power. Service providers, on the other hand, provide services and collaborative work environment to stand out.

Supplier Power

  • The number of raw material suppliers and their product quality have significantly been increasing

  • With the increase in outsourcing penetration rates by big pharmaceutical players, supplier power would increase from the currently low-to-medium level in the next few years

  • Suppliers tend to have moderate product differentiation and distribution channels

Barriers to New Entrants

  • The entry barrier would remain high, due to high economics of scale, investment cost, and stringent government regulatory mandate and legal barriers

Intensity of Rivalry

  • Industrial competition is expected to further increase, with new players and improved product differentiation inflow into the market

  • Supplier capabilities, strategies and innovations are growing with the demand of animals for testing

Threat of Substitutes

  • Threat of substitutes is moderately high in the market, as alternate testing methods are gaining traction, due to ethical and animal rights regulations in many European countries to replace in-vivo testing methodologies. Product differentiation and ease of substitution are extremely high

Buyer Power

  • Pharma’s buying power will remain moderately high, as the number of buyers is steadily increasing with increased purchase quantity

  • CROs are also expecting a good volume of business from small Biotech companies in the next 1–2 years, due to the increase in venture funding for small Biotechs

  • Product dependency and backward integration are moderate on the buyer’s side

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

“Rethinking Digital Procurement”: Joins us for a discussion on July 27